Anzeige
Mehr »
Sonntag, 15.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
41 Leser
Artikel bewerten:
(0)

Angioplasty Balloon Market Size to Reach USD 2.9 Billion by 2024: Grand View Research, Inc.

SAN FRANCISCO, February 1, 2017 /PRNewswire/ --

The global angioplasty balloon market is expected to reach a value of USD 2.9 billion by 2024, according on a new report by Grand View Research, Inc. The growth of the market is attributed to favorable government policies, approval & commercialization of several angioplasty balloons, and increasing coronary & peripheral interventions. Angioplasty is a minimally invasive procedure, hence patients and surgeons prefer this procedure over high cost stent placements.

(Logo: http://photos.prnewswire.com/prnh/20150105/723757 )

Furthermore, advancements in the angioplasty balloons are likely to propel the market. For instance, in December 2014 Medtronic plc received a U.S.FDA approval for their drug coated balloon IN. PACT Admiral for the treatment of peripheral artery disease. Approval and commercialization of cutting and scoring balloons, such as Flextome, AngioSculpt, TREK and MINI TREK balloon, rising adoption of new balloons, and lower cost as compared to stent placement are likely to drive the market during the forecast period.

Browse full research report with TOC on "Angioplasty Balloons Market Analysis By Type (Normal Balloons, Drug Eluting Balloons, Cutting Balloons, Scoring Balloons), By Application (Peripheral, Coronary), By End Use, By Region, And Segment Forecasts, 2013 - 2024" at: http://www.grandviewresearch.com/industry-analysis/angioplasty-balloons-market

Further key findings from the report suggest

  • Normal balloon segment dominated the market in 2015 due to low cost and favorable U.S. FDA policies. Its ability to treat coronary artery obstruction is further expected to propel the market growth.
  • Drug-eluting balloon segment is anticipated to be the most lucrative during the forecast period. This is attributed to increasing investment in R & D by major players and lower restenosis rates.
  • Coronary balloon dominated in 2015 and is expected to maintain its dominance during forecast period. This is due to rising incidence rate of coronary artery diseases around the globe.
  • Peripheral is the most lucrative segment owing to launching of new peripheral products in recent years. Market players are in a process of introducing newer products with increased efficiency.
  • Ambulatory surgery centers dominated the end use segment in 2015. They accounted for the highest share of the vertical as they help minimize the medical expenses and hospital stay.
  • Regionally, North America dominated the market in 2015 and is expected to maintain its position during the forecast period due to local presence of major market players and high cost of devices as compared to other regions.
  • Asia Pacific is anticipated to be fastest growing segment during the forecast period due to rising healthcare expenditure, growing investment of key market players in the region, and high patient population.
  • Some of the market players operating in the industry are Abbott; Boston Scientific Corporation; Cardinal Health (Cordis); Cook Medical; C. R. Bard, Inc.; ENDOCOR GmbH; Medtronic; Spectranetics; and Johnson & Johnson.

Browse related reports by Grand View Research:

  • Home Healthcare Market - http://www.grandviewresearch.com/industry-analysis/home-healthcare-industry
  • Home Infusion Therapy Market - http://www.grandviewresearch.com/industry-analysis/home-infusion-therapy-market
  • Surgical Equipment/Instruments Market - http://www.grandviewresearch.com/industry-analysis/surgical-equipment-market
  • Prefilled Syringes Market - http://www.grandviewresearch.com/industry-analysis/pre-filled-syringes-market

Grand View Research has segmented the angioplasty balloons market by balloons type, application, end-use, and region:

  • Type Outlook (Market Revenue in USD Million, 2013 - 2024)
    • Normal Balloons
    • Drug Eluting Balloons
    • Cutting Balloons
    • Scoring Balloons
  • Application Outlook (Market Revenue in USD Million, 2013 - 2024)
    • Coronary
    • Peripheral
  • End Use Outlook (Market Revenue in USD Million, 2013 - 2024)
    • Ambulatory Surgery Centers (ASCs)
    • Hospitals
    • Catheterization Laboratories (Cath Lab)
  • Regional Outlook (Market Revenue in USD Million, 2013 - 2024)
    • North America
      • U.S.
      • Canada
    • Europe
      • UK
      • Germany
    • Asia Pacific
      • Japan
      • China
    • Latin America
      • Brazil
      • Mexico
    • Middle East and Africa
      • South Africa

Read Our Blog - Angioplasty Balloons Market: Rising Peripheral and Coronary Interventions to Propel the Market by 2024

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. Thecompany provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc.
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com

Web: http://www.grandviewresearch.com


© 2017 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.